Skip to main content
Top
Published in: Breast Cancer 5/2018

01-09-2018 | Original Article

Characterization of an in vitro model system to explore control of tumor invasion of EMT6 and 4THM breast tumors by CD200:CD200R interactions

Published in: Breast Cancer | Issue 5/2018

Login to get access

Abstract

Background and purpose

In BALB/c mice with transplantable breast tumors, we showed that CD200R1KO mice were cured of local and metastatic growth of EMT6 cells following surgical resection of localized tumor and immunization with irradiated cells along with CpG as adjuvant. On the other hand, wild-type (WT) animals treated in the same fashion develop pulmonary and liver metastases within 20 days of surgery. To develop an in vitro system which would mimic the in vivo model and allow exploration of factors controlling tumor invasion as a precursor to in vivo metastasis, we have developed and characterized a two-phase culture system.

Methods

Bone marrow mesenchymal stromal cells (BMMSCs) from WT, CD200KO or CD200R1KO mice were admixed with T lymphocytes from tumor-immunized mice and cultured in collagen gels. Tumor cells were subsequently seeded in fresh medium above this gel 1d later. We then investigated the regulation of tumor invasion from the liquid to the gel layer. Tumor cells were measured in the gel layer following collagenase digestion and cultured at limiting dilution—an aliquot of the digest was also analyzed for cytokine levels in ELISA.

Results

BMMSCs from WT, CD200KO and CD200R1KO mice all augmented seeding/growth of EMT6 and 4THM tumor cells into the collagen matrix. Inclusion of IL-6 and IL-17 in the gel matrix was associated with increased invasion of tumor cells into this layer. Inclusion of DLN cells from EMT6 immune or 4THM immune mice further modified tumor invasion, with increased tumor numbers seen using stromal elements from CD200 and CD200R1KO mice and DLN from 4THM immune, while CD200R1KO-derived DLN of EMT6 immune mice attenuated tumor invasion, despite inclusion of IL-6/IL-17 in the gel layer.

Conclusion

Multiple factors can regulate tumor invasion, including micro-environmental stromal elements, IL-6/IL-17, and signals from tumor-derived DLN cells.
Literature
1.
go back to reference Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A. Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200 Cancer Immunol. Immunotherapy. 2008;57:987–96.CrossRef Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A. Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200 Cancer Immunol. Immunotherapy. 2008;57:987–96.CrossRef
2.
go back to reference Moreaux J, Veyrune JL, Reme T, DeVos J, Klein B. CD200: a putative therapeutic target in cancer. Biochem Biophys Res Commun. 2008;366:117–22.CrossRefPubMed Moreaux J, Veyrune JL, Reme T, DeVos J, Klein B. CD200: a putative therapeutic target in cancer. Biochem Biophys Res Commun. 2008;366:117–22.CrossRefPubMed
3.
go back to reference McWhirter JR, KretzRommel A, Saven A, et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Nat Acad Sci USA. 2006;103:1041–6.CrossRefPubMed McWhirter JR, KretzRommel A, Saven A, et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Nat Acad Sci USA. 2006;103:1041–6.CrossRefPubMed
4.
go back to reference Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL. Co-expression of the tolerogenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun. 2007;364:778–82.CrossRefPubMedPubMedCentral Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL. Co-expression of the tolerogenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun. 2007;364:778–82.CrossRefPubMedPubMedCentral
5.
go back to reference Gorczynski RM, Chen Z, Diao J, et al. Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice. Breast Cancer Res Treat. 2010;123:405–15.CrossRefPubMed Gorczynski RM, Chen Z, Diao J, et al. Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice. Breast Cancer Res Treat. 2010;123:405–15.CrossRefPubMed
6.
go back to reference Gorczynski RM, Clark DA, Erin N, Khatri I. Role of CD200 in regulation of tumor invasion of EMT6 tumor cells in mice. Breast Cancer Res Treat. 2011;130:49–60.CrossRefPubMed Gorczynski RM, Clark DA, Erin N, Khatri I. Role of CD200 in regulation of tumor invasion of EMT6 tumor cells in mice. Breast Cancer Res Treat. 2011;130:49–60.CrossRefPubMed
7.
go back to reference Erin N, Podnos A, Tanriover G, Duymus O, Cote E, Khatri I, Gorczynski RM. Bidirectional effect of CD200 on breast cancer development and tumor invasion with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response. Oncogene. 2014;34:3860.CrossRefPubMed Erin N, Podnos A, Tanriover G, Duymus O, Cote E, Khatri I, Gorczynski RM. Bidirectional effect of CD200 on breast cancer development and tumor invasion with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response. Oncogene. 2014;34:3860.CrossRefPubMed
8.
go back to reference De Visser KE, Eichten A, Lisa M. Coussens paradoxical roles of the immune system during cancer development. Nat Cancer Rev. 2006;6:24–37.CrossRef De Visser KE, Eichten A, Lisa M. Coussens paradoxical roles of the immune system during cancer development. Nat Cancer Rev. 2006;6:24–37.CrossRef
9.
go back to reference Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Cole VD, Kramer K, Wexler LH, Narendran A, Schwartz GK, Healey JH, Sandstrom P, Labori KJ, Kure EH, Grandgenett PM, Hollingsworth MA, de Sousa M, Kaur S, Jain M, Mallya K, Batra SK, Jarnagin WR, Brady MS, Fodstad O, Muller V, Pantel K, Minn AJ, Bissell MJ, Garcia BA, Kang Y, Rajasekhar VK, Ghajar CM, Matei I, Peinado H, Bromberg J, Lyden D. Tumour exosome integrins determine organotropic tumor invasion. Nature. 2015;527:329–35. https://doi.org/10.1038/nature15756.CrossRefPubMedPubMedCentral Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Cole VD, Kramer K, Wexler LH, Narendran A, Schwartz GK, Healey JH, Sandstrom P, Labori KJ, Kure EH, Grandgenett PM, Hollingsworth MA, de Sousa M, Kaur S, Jain M, Mallya K, Batra SK, Jarnagin WR, Brady MS, Fodstad O, Muller V, Pantel K, Minn AJ, Bissell MJ, Garcia BA, Kang Y, Rajasekhar VK, Ghajar CM, Matei I, Peinado H, Bromberg J, Lyden D. Tumour exosome integrins determine organotropic tumor invasion. Nature. 2015;527:329–35. https://​doi.​org/​10.​1038/​nature15756.CrossRefPubMedPubMedCentral
13.
go back to reference van Solingen C, Seghers L, Bijkerk R, Duijs JM, Roeten MK, van Oeveren-Rietdijk AM, Baelde HJ, Monge M, Vos JB, de Boer HC, Quax PH, Rabelink TJ, van Zonneveld AJ. Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis. J Cell Mol Med. 2009;13:1577–85.CrossRefPubMed van Solingen C, Seghers L, Bijkerk R, Duijs JM, Roeten MK, van Oeveren-Rietdijk AM, Baelde HJ, Monge M, Vos JB, de Boer HC, Quax PH, Rabelink TJ, van Zonneveld AJ. Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis. J Cell Mol Med. 2009;13:1577–85.CrossRefPubMed
14.
go back to reference Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438:685–9.CrossRefPubMed Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438:685–9.CrossRefPubMed
20.
go back to reference Zhao P, Chen Y, Yue Z, Yuan Y, Wang X. Bone marrow mesenchymal stem cells regulate stemness of multiple myeloma cell lines via BTK signaling pathway. Leuk Res. 2017;57:20–6.CrossRefPubMed Zhao P, Chen Y, Yue Z, Yuan Y, Wang X. Bone marrow mesenchymal stem cells regulate stemness of multiple myeloma cell lines via BTK signaling pathway. Leuk Res. 2017;57:20–6.CrossRefPubMed
21.
go back to reference Zhu F, Khatri I, Spaner D, Gorczynski RM. An autologous tumor vaccine for CLL. Leuk Res. 2018: in press. Zhu F, Khatri I, Spaner D, Gorczynski RM. An autologous tumor vaccine for CLL. Leuk Res. 2018: in press.
22.
go back to reference Podnos A, Clark DA, Erin N, Yu K, Gorczynski RM. Further evidence for a role of tumor CD200 expression in breast cancer tumor invasion: decreased tumor invasion in CD200R1KO mice or using CD200-silenced EMT6. Breast Cancer Res Treat. 2012;136:117–27.CrossRefPubMed Podnos A, Clark DA, Erin N, Yu K, Gorczynski RM. Further evidence for a role of tumor CD200 expression in breast cancer tumor invasion: decreased tumor invasion in CD200R1KO mice or using CD200-silenced EMT6. Breast Cancer Res Treat. 2012;136:117–27.CrossRefPubMed
27.
go back to reference Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpé S, Vermeulen PB, Dirix LY. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res. 2004;10:7157–62.CrossRefPubMed Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpé S, Vermeulen PB, Dirix LY. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res. 2004;10:7157–62.CrossRefPubMed
31.
go back to reference Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL-6 secretion. Proc Natl Acad Sci USA. 2011;108:1397–402.CrossRefPubMed Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL-6 secretion. Proc Natl Acad Sci USA. 2011;108:1397–402.CrossRefPubMed
32.
go back to reference Oh K, Lee OY, Shon SY, Nam O, Ryu PM, Seo MW, Lee DS. A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous tumor invasion through IL-6 trans-signaling in a murine model. Breast Cancer Res. 2013;15(5):79.CrossRef Oh K, Lee OY, Shon SY, Nam O, Ryu PM, Seo MW, Lee DS. A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous tumor invasion through IL-6 trans-signaling in a murine model. Breast Cancer Res. 2013;15(5):79.CrossRef
33.
go back to reference Roy LD, Sahraei M, Schettini JL, Gruber HE, Besmer DM, Mukherjee P. Systemic neutralization of IL-17A significantly reduces breast cancer associated tumor invasion in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches. BMC Cancer. 2014;27(14):225. https://doi.org/10.1186/1471-2407-14-225.CrossRef Roy LD, Sahraei M, Schettini JL, Gruber HE, Besmer DM, Mukherjee P. Systemic neutralization of IL-17A significantly reduces breast cancer associated tumor invasion in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches. BMC Cancer. 2014;27(14):225. https://​doi.​org/​10.​1186/​1471-2407-14-225.CrossRef
37.
go back to reference McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and tumor invasion. Nature Cell Biol. 2014;16:717–27.CrossRefPubMed McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and tumor invasion. Nature Cell Biol. 2014;16:717–27.CrossRefPubMed
38.
go back to reference Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10:593–601.CrossRefPubMed Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10:593–601.CrossRefPubMed
39.
go back to reference Jiang S, Zhang H-W, Lu M-H, He X-H, Li Y, Gu H, et al. MicroRNA-155 Functions as an OncomiR in breast cancer by targeting the Suppressor of Cytokine Signaling 1 Gene. Cancer Res. 2010;70:3119–27.CrossRefPubMed Jiang S, Zhang H-W, Lu M-H, He X-H, Li Y, Gu H, et al. MicroRNA-155 Functions as an OncomiR in breast cancer by targeting the Suppressor of Cytokine Signaling 1 Gene. Cancer Res. 2010;70:3119–27.CrossRefPubMed
44.
go back to reference Cioffi M, Trabulo SM, Vallespinos M, Raj D, Kheir TB, Lin ML, Begum J, Baker AM, Amgheib A, Saif J, Perez M, Soriano J, Desco M, Gomez-Gaviro MV, Cusso L, Megias D, Aicher A, Heeschen C. The miR-25-93-106b cluster regulates tumor tumor invasion and immune evasion via modulation of CXCL12 and PD-L1. Mol Cancer. 2017;16:148. https://doi.org/10.1186/s12943-017-0718-4.CrossRef Cioffi M, Trabulo SM, Vallespinos M, Raj D, Kheir TB, Lin ML, Begum J, Baker AM, Amgheib A, Saif J, Perez M, Soriano J, Desco M, Gomez-Gaviro MV, Cusso L, Megias D, Aicher A, Heeschen C. The miR-25-93-106b cluster regulates tumor tumor invasion and immune evasion via modulation of CXCL12 and PD-L1. Mol Cancer. 2017;16:148. https://​doi.​org/​10.​1186/​s12943-017-0718-4.CrossRef
46.
47.
go back to reference Gorczynski RM, Zhu F, Chen Z, Kos O, Khatri I. A comparison of serum miRNAs influencing metastatic growth of EMT6 vs 4THM tumor cells in wild-type and CD200R1KO mice. Breast Cancer Res Treat. 2017;162:255–66.CrossRefPubMed Gorczynski RM, Zhu F, Chen Z, Kos O, Khatri I. A comparison of serum miRNAs influencing metastatic growth of EMT6 vs 4THM tumor cells in wild-type and CD200R1KO mice. Breast Cancer Res Treat. 2017;162:255–66.CrossRefPubMed
Metadata
Title
Characterization of an in vitro model system to explore control of tumor invasion of EMT6 and 4THM breast tumors by CD200:CD200R interactions
Publication date
01-09-2018
Published in
Breast Cancer / Issue 5/2018
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-018-0851-y

Other articles of this Issue 5/2018

Breast Cancer 5/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine